Last reviewed · How we verify
CRD007
At a glance
| Generic name | CRD007 |
|---|---|
| Also known as | Pemirolast sodium, Pemirolast |
| Sponsor | RSPR Pharma AB |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pemirolast in Allergen Challenge (PEMAG) (PHASE2)
- Safety and Efficacy of CRD007 in Adult Asthma Subjects (PHASE2)
- RSPR-007 Mannitol Challenge Trial (PHASE2)
- Study in Healthy Volunteers to Document Safety and Tolerability of Increasing Doses Pemirolast (PHASE1)
- Pharmacokinetics of CRD007 in Patients With Abdominal Aorta Aneurisms. (PHASE1)
- CRD007 for the Treatment of Abdominal Aorta Aneurysm (The AORTA Trial) (PHASE2)
- CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CRD007 CI brief — competitive landscape report
- CRD007 updates RSS · CI watch RSS
- RSPR Pharma AB portfolio CI